Opus Genetics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-49.6M | $-57.5M | $-10.0M | $17.9M | $-56.7M | $-24.6M | $-6.2M | $-14.4M |
| Depreciation & Amortization | — | — | — | — | — | — | $41.0K | $48.2K |
| Depreciation | $53.0K | $10.0K | $6.0K | $4.0K | $4.0K | $8.0K | $3.0K | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.4M | $3.4M | $3.5M | $1.8M | $1.9M | $1.5M | $308.0K | $1.2M |
| Net Cash from Operating Activities | $-35.3M | $-25.6M | $-1.1M | $14.3M | $-19.4M | $-6.8M | $-3.6M | $-18.8M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | $0 | $25.0K | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $1.2M | $0 | $0 | $-100.0K | $539.0K | $-25.0K | $11.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $50.0M | $4.2M | $9.0M | $3.8M | $27.6M | $21.1M | $4.7M | $6.8M |
| Net Change in Cash | — | — | — | — | — | — | — | $-154.9K |
| Free Cash Flow | — | — | — | — | — | $-6.8M | $-3.6M | — |